Olanzapine
Olanzapin Krka contains the active substance olanzapine. Olanzapin Krka belongs to a group of medicines called antipsychotics and is used to treat:
It has been shown that Olanzapin Krka prevents the recurrence of these symptoms in patients with bipolar affective disorder who have responded well to olanzapine treatment for a manic episode.
Before starting to take Olanzapin Krka, you should consult your doctor or pharmacist.
If you have any of the following diseases, you should inform your doctor as soon as possible:
If you have dementia and have had a stroke or "mini" stroke, you (or your caregiver) should tell your doctor.
Routinely, as a precaution, in people over 65 years of age, the doctor may check blood pressure.
Olanzapin Krka is not intended for use in patients under 18 years of age.
People taking Olanzapin Krka may only take other medicines with the consent of their doctor.
Taking Olanzapin Krka in combination with antidepressant, sedative, or sleeping medicines may cause drowsiness.
You should tell your doctor about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
In particular, you should tell your doctor about:
You should not drink alcohol after taking Olanzapin Krka, as this medicine in combination with alcohol may cause drowsiness.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor before taking this medicine. Olanzapin Krka should not be taken by breastfeeding women, as small amounts of the medicine may pass into breast milk.
In newborns whose mothers took Olanzapin Krka in the last trimester (last 3 months of pregnancy), the following symptoms may occur: trembling, muscle stiffness, and/or weakness, drowsiness, excitement, breathing difficulties, and feeding difficulties. If you notice such symptoms in your child, you should contact your doctor.
Olanzapin Krka may cause drowsiness. If drowsiness occurs, you should not drive vehicles or operate any machines or mechanical devices. You should inform your doctor.
If your doctor has told you that you have an intolerance to some sugars, you should contact your doctor before taking this medicine.
This medicine should always be taken as directed by your doctor. If you are unsure, you should consult your doctor or pharmacist.
Your doctor will decide how many tablets and how long you should take Olanzapin Krka. The daily dose of Olanzapin Krka is from 5 mg to 20 mg.
If the symptoms of the disease recur, you should inform your doctor. However, you should not stop taking Olanzapin Krka unless your doctor decides to do so.
Olanzapin Krka tablets should be taken once a day as directed by your doctor. You should try to take the medicine at the same time every day. It does not matter whether you take the tablets with or without food.
You should swallow the tablet whole, with a glass of water.
In patients who have taken a higher dose of Olanzapin Krka than recommended, the following symptoms have occurred: rapid heartbeat, excitement/aggression, speech disorders, abnormal movements (especially of the face and tongue), decreased level of consciousness.
Other symptoms include confusion (disorientation), seizures, epilepsy, coma, a syndrome of symptoms with fever, rapid breathing, sweating, muscle stiffness, and drowsiness; slow breathing rate, choking, high or low blood pressure, abnormal heart rhythm.
You should contact your doctor immediately or go to the hospital if you experience any of these symptoms. You should show your doctor the packaging of the tablets.
As soon as you remember, you should take the tablets. You should not take a double dose to make up for the missed dose.
If you feel better, you should not stop taking the tablets. It is important to take Olanzapin Krka for as long as your doctor recommends.
If you suddenly stop taking Olanzapin Krka, you may experience symptoms such as sweating, insomnia, trembling, anxiety, or nausea and vomiting. Your doctor may suggest gradually reducing the dose of Olanzapin Krka before stopping it.
If you have any further questions about the use of this medicine, you should consult your doctor or pharmacist.
Like all medicines, Olanzapin Krka can cause side effects, although not everybody gets them.
You should tell your doctor immediately if you experience:
Very common side effects (may occur in more than 1 in 10 patients) include:
weight gain; drowsiness and increased prolactin levels in the blood. In the early stages of treatment, dizziness or fainting (with a slow heart rate) may occur, especially when standing up from a lying or sitting position. These symptoms usually go away on their own, but if they persist, you should inform your doctor.
Common side effects (may occur in up to 1 in 10 patients) include: changes in the number of certain blood cells and lipid levels in the blood; increased blood sugar and urine levels; increased levels of uric acid and creatine phosphokinase in the blood; increased appetite; dizziness; restlessness; tremors; movement disorders (dyskinesias); constipation; dry mouth; weakness; extreme fatigue; water retention in the body causing swelling of the hands, feet, or ankles; fever; joint pain; sexual disorders, such as decreased libido in men and women or erectile dysfunction in men.
Uncommon side effects (may occur in up to 1 in 100 patients) include: hypersensitivity (e.g., swelling in the mouth and throat, itching, rash); diabetes or worsening of its course, occasionally with ketoacidosis (presence of ketone bodies in the blood and urine) or coma; seizures, usually in patients who have had seizures (epilepsy) before; muscle stiffness or spasm (including eye movements); restless legs syndrome; speech disorders; stuttering; slow heart rate; hypersensitivity to sunlight; nosebleeds; abdominal bloating; memory loss or lack of memory; urinary incontinence, difficulty urinating; hair loss; absence or decrease of menstrual periods; changes in the breasts in men and women, such as milk secretion outside of breastfeeding or unusual breast enlargement.
Rare side effects (may occur in up to 1 in 1000 patients) include: decreased body temperature; heart rhythm disorders; sudden death from an unknown cause; pancreatitis causing severe abdominal pain, fever, and nausea; liver disease characterized by a change in skin and white eye color to yellow; muscle disease characterized by unexplained muscle pain and weakness; prolonged and/or painful erections.
Very rare side effects include severe allergic reactions, such as drug reaction with eosinophilia and systemic symptoms (DRESS). In DRESS, initial symptoms are flu-like with a rash on the face, followed by a widespread rash, high fever, enlarged lymph nodes, elevated liver enzyme activity, and increased levels of a specific type of white blood cell (eosinophilia).
In elderly patients with dementia, Olanzapin Krka may cause: stroke, pneumonia, urinary incontinence, falls, extreme fatigue, visual hallucinations, elevated body temperature, skin redness, and gait disturbances. In these patient groups, several fatal cases have been reported.
In patients with Parkinson's disease, Olanzapin Krka may worsen side effects.
If you experience any side effects, including those not listed in this leaflet, you should tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Al. Jerozolimskie 181C, 02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
e-mail: ndl@urpl.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
Store in the original packaging to protect from light and moisture.
There are no special precautions for storage temperature of the medicinal product.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month stated.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Olanzapin Krka, 5 mg, tablets: round (diameter 7 mm), slightly convex on both sides, light yellow tablets with possible single yellow spots and the inscription "5"
Olanzapin Krka, 10 mg, tablets: round (diameter 9 mm), slightly convex on both sides, light yellow tablets with possible single yellow spots and the inscription "10"
Olanzapin Krka, 15 mg, tablets: round (diameter 11 mm), slightly convex on both sides, light yellow tablets with possible single yellow spots and the inscription "15"
Olanzapin Krka, 20 mg, tablets: round (diameter 12 mm), slightly convex on both sides, light yellow tablets with possible single yellow spots and the inscription "20"
Packaging: 28 and 56 tablets in blisters in a cardboard box
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
KRKA-POLSKA Sp. z o.o., ul. Równoległa , 02-235 Warsaw
Date of last revision of the leaflet:17.07.2019
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.